CD30-positive cutaneous T-cell lymphoma and response to Brentuximab vedotin: 2 illustrative cases

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 3, 2013, Pages 319-323

  Mody, Kabir ^a   Wallace, Jill S ^a   Stearns, Diane M ^a   Bowers, George ^b   Lacy, Shannon R ^a   Levy, Norman B ^a   Zug, Kathryn A ^a   Lansigan, Frederick ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b Hampshire Hematology Oncology   (United States)

Author keywords

Cutaneous anaplastic large cell lymphoma; Cutaneous T cell lymphoma; Mycosis fungoides

Indexed keywords

BRENTUXIMAB VEDOTIN; CD2 ANTIGEN; CD3 ANTIGEN; CD30 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; INTERLEUKIN 2 RECEPTOR ALPHA; LEUKOSIALIN; PREDNISONE; STEROID; T LYMPHOCYTE RECEPTOR BETA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; VINCRISTINE;

AGED; ARM; ARTICLE; ATROPHY; AXILLA; BURN; BUTTOCK; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CASE REPORT; CELL TRANSFORMATION; CHROMATIN; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG RESPONSE; EPIDERMIS; ERYTHEMA; EXOCYTOSIS; FLOW CYTOMETRY; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; INGUINAL REGION; KIDNEY FAILURE; LARGE CELL LYMPHOMA; LEG; LICHENOID; LYMPHOCYTE; LYMPHOCYTIC INFILTRATION; MALE; MOLECULAR CLONING; MULTIPLE CYCLE TREATMENT; MYCOSIS FUNGOIDES; NECROSIS; NEUROPATHY; PHYSICAL EXAMINATION; PRURITUS; RASH; SCALP; SCALP TUMOR; SKIN DEFECT; SKIN PAIN; STEROID THERAPY; THIGH; THORAX WALL; TRUNK; TUMOR BIOPSY; ULTRAVIOLET RADIATION;

AGED; AGED, 80 AND OVER; ANTIGENS, CD30; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, T-CELL, CUTANEOUS; MALE;

EID: 84877726983     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2012.12.008     Document Type: Article

References (21)

1. A. Younes, M.E. Kadin Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy J Clin Oncol 21 2003 3526 3534 (Pubitemid 46594087)
2. C.S. Duckett, C.B. Thompson CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival Genes Dev 11 1997 2810 2821 (Pubitemid 27481682)
3. Z.G. Tian, D.L. Longo, S. Funakoshi In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts Cancer Res 55 1995 5335 5341
4. A. Forero-Torres, J.P. Leonard, A. Younes A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma Br J Haematol 146 2009 171 179
5. G.A. Wiseman, C.A. White, M. Stabin Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma Eur J Nucl Med Mol Imaging 27 2000 766 777 (Pubitemid 30456759)
6. T.E. Witzig, C.A. White, G.A. Wiseman Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma J Clin Oncol 17 1999 3793 3803
7. J.M. Vose, R.L. Wahl, M. Saleh Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas J Clin Oncol 18 2000 1316 1323 (Pubitemid 30159851)
8. M.S. Kaminski, J. Estes, K.R. Zasadny Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the university of Michigan experience Blood 96 2000 1259 1266 (Pubitemid 30658452)
9. J. Katz, J.E. Janik, A. Younes Brentuximab vedotin (SGN-35) Clin Cancer Res 17 2011 6428 6436
10. S.C. Alley, N.M. Okeley, P.D. Senter Antibody-drug conjugates: targeted drug delivery for cancer Curr Opin Chem Biol 14 2010 529 537
11. E. Olsen, M. Duvic, A. Frankel Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma J Clin Oncol 19 2001 376 388 (Pubitemid 32112849)
12. H.M. Prince, M. Duvic, A. Martin Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma J Clin Oncol 28 2010 1870 1877
13. J. Lundin, H. Hagberg, R. Repp Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome Blood 101 2003 4267 4272 (Pubitemid 36857787)
14. G.A. Kennedy, J.F. Seymour, M. Wolf Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab Eur J Haematol 71 2003 250 256 (Pubitemid 37174695)
15. M. Duvic, K. Hymes, P. Heald Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results J Clin Oncol 19 2001 2456 2471 (Pubitemid 32391217)
16. S. Bates, R. Piekarz, J. Wright Final clinical results of a phase 2 NCI multicenter study of Romidepsin in recurrent cutaneous T-cell lymphoma (molecular analyses included) [Abstract] ASH Annual Meeting Abstracts 112 2008 1568
17. E.A. Olsen, Y.H. Kim, T.M. Kuzel Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma J Clin Oncol 25 2007 3109 3115 (Pubitemid 47218059)
18. O.A. O'Connor, B. Pro, L. Pinter-Brown PROPEL: a multi-center phase 2 open-label study of pralatrexate (PDX) with vitamin B12 and folic acid supplementation in patients with relapsed or refractory peripheral T-cell lymphoma [Abstract] ASH Annual Meeting Abstracts 112 2008 261
19. S.M. Horwitz, M. Duvic, Y. Kim Pralatrexate (PDX) is active in cutaneous T-cell lymphoma: preliminary results of a multi-center dose-finding trial [Abstract] ASH Annual Meeting Abstracts 112 2008 1569
20. P.L. Zinzani, G. Baliva, M. Magagnoli Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients J Clin Oncol 18 2000 2603 2606 (Pubitemid 30432527)
21. Duvic M, Tetzlaff M, Clos AL, et al. Results of a phase II trial of brentuximab vedotin (SGN-35) for CD30+ cutaneous T-cell lymphomas and lymphoproliferative disorders. ASH Annual Meeting Abstracts; 120:Abstract 3688.